Lifeboat Foundation

Individuals suffering from severe depression may find relief from just a single dose of a synthetic version of psilocybin, or “magic mushrooms,” according to a new study published this week.

The findings, which were published Wednesday by The New England Journal of Medicine, come from a double-blind trial involving 233 “randomly assigned adults with treatment-resistant depression [who received] a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support.”

“In this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects,” the authors wrote in their conclusions, adding that “larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder.”

The views expressed are those of the authors and not necessarily those of the NHS, the National Institute for Health or Care Research, or the Department of Health and Social Care in the United Kingdom.

This article was updated on November 3, 2022, at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

CHICAGO, Nov 29 (Reuters) — The first big breakthrough in 30 years of Alzheimer’s research is providing momentum for clinical trials of “cocktail” treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives.

Drugmakers Eisai Co Ltd (4523.T) and Biogen (BIIB.O)

Reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo [ read more.

Music is Truth Police by White Bat AudioDespite personal controversies I’m interested to see where the science goes.

‘This is the first drug that provides a real treatment option,’ says leading researcher Scientists are hailing a historic step in the fight against Alzheimer’s, after a drug was proven to slow the disease in long-awaited clinical trials. The breakthrough comes after decades of failed attempts to find a way to do so, and has prompted hope among experts that it could eventually pave the way for treatments which could ultimately lead to a cure.

Year 2021 😁

Conducting medical research on lab-printed brains could be better than animal studies.

Summary: Researchers have identified two proteins that prevent the formation of scars in the brain and help promote the regeneration of new neural tissue.

Source: LMU

LMU researchers demonstrate in a zebrafish model that two proteins prevent scar formation in the brain, thereby improving the ability of tissue to regenerate.

3D structures of cells and connections reveal new role for an understudied brain cell.

Talk kindly contributed by Michael Levin in SEMF’s 2022 Spacious Spatiality.

https://semf.org.es/spatiality.

Continue reading “Michael Levin | Cell Intelligence in Physiological & Morphological Spaces” »